FibroGen, Inc. (FGEN)
NASDAQ: FGEN · Real-Time Price · USD
11.58
+0.27 (2.39%)
Sep 5, 2025, 12:35 PM - Market open

Company Description

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs.

Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.

Its pipeline products include FG-3165 and FG-3175, an anti-GAL-9 antibody for treatment of solid tumors.

The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

FibroGen, Inc.
FibroGen logo
CountryUnited States
Founded1993
IPO DateNov 14, 2014
IndustryBiotechnology
SectorHealthcare
Employees225
CEOThane Wettig

Contact Details

Address:
350 Bay Street, Suite 10 #6009
San Francisco, California 94133
United States
Phone415 978 1200
Websitefibrogen.com

Stock Details

Ticker SymbolFGEN
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0000921299
CUSIP Number31572Q881
ISIN NumberUS31572Q8814
SIC Code2834

Key Executives

NamePosition
Thane WettigChief Executive Officer and Director
David DeLuciaChief Financial Officer
Christine L. ChungSenior Vice President of China Operations
John AldenCorporate Secretary and General Counsel

Latest SEC Filings

DateTypeTitle
Sep 2, 20258-KCurrent Report
Aug 18, 20258-KCurrent Report
Aug 15, 2025SCHEDULE 13G/AFiling
Aug 14, 20258-KCurrent Report
Aug 11, 202510-QQuarterly Report
Aug 11, 20258-KCurrent Report
Jul 29, 2025SCHEDULE 13G/AFiling
Jul 14, 20258-KCurrent Report
Jun 13, 20258-KCurrent Report
Jun 12, 20258-KCurrent Report